Status:
RECRUITING
Molecular Diagnosis of Systemic Autoinflammatory Diseases
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Inflammatory Disease
Genetic Disease
Eligibility:
All Genders
1-120 years
Brief Summary
Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of p...
Detailed Description
SAIDs are characterized by long dormant periods with no or only minor clinical symptoms interrupted by febrile crises accompanied by serous and synovial membrane inflammation that spontaneously resolv...
Eligibility Criteria
Inclusion
- A patient presenting with a clinical and biological aseptic inflammatory syndrome associating one or more of the following signs: spontaneously resolving fever, abdominal (pain, diarrhea), locomotor (arthralgia, myalgia), thoracic (pain, pericarditis), cutaneous, sensory (uveitis, deafness), or renal (amyloidosis) involvement.
Exclusion
- Adult subject to legal protection measures (guardianship, curatorship, safeguard of justice).
Key Trial Info
Start Date :
May 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 2 2033
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05364294
Start Date
May 18 2022
End Date
May 2 2033
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Trousseau Hospital
Paris, France, 75012